Homepage Top Section2

The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in the Chinese city in Hubei

Imfinzi is a human monoclonal antibody that binds to PD-L1 and restricts the interaction of PD-L1 with PD-1 and CD80, helping to oppose the tumour’s immune-evading tactics and

Imbruvica is already approved in Europe for chronic lymphocytic leukaemia as a monotherapy or in combination with obinutuzumab in patients who were previously untreated for their condition. The

Via its subsidiary, Merck has completed the cash tender offer to acquire all the outstanding shares of ArQule at a purchase price of $20 per share. Merck said

As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop T-cell therapy candidates

Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is

SM-88 is one of the cancer metabolism-based therapies (CMBTs) that are being developed by Tyme Technologies. According to the company, CMBTs are investigational compounds that can potentially disrupt

Reported to be the world’s largest independent funder of cancer research, Cancer Research UK will provide funding for the exploratory development of Bicycle’s BT7401 candidate through a phase

As per the deal announced in December 2019, Charles River Laboratories offered to buy HemaCare for $25.40 per share. The California-based company, which will now operate under Charles